Press Releases May 7, 2026 07:30 AM

Harvard Bioscience to Participate in Upcoming Investor Conferences

Harvard Bioscience announces CEO and CFO participation in upcoming virtual investor conferences

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
HBIO

Harvard Bioscience, Inc., a developer and manufacturer of life science technologies, announced that its CEO John Duke and CFO Mark Frost will participate in two upcoming virtual investor conferences in May 2026, including the Sidoti Micro Cap Conference and the Benchmark Healthcare House Call Virtual Conference. The company will provide a live webcast and archived replay of the Sidoti event on its investor relations website.

Harvard Bioscience to Participate in Upcoming Investor Conferences
HBIO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Harvard Bioscience executives to present at Sidoti Micro Cap and Benchmark Healthcare virtual investor conferences.
  • The company operates internationally with a focus on life science technologies aiding pharmaceutical and therapy development.
  • Live webcast and replay of presentations will be made available to investors online.

HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost’s participation in the following upcoming investor events.

Sidoti Micro Cap Conference
Location: Virtual
Date: Thursday, May 21, 2026
Fireside Chat Presentation: 11:30 AM ET

Benchmark (StoneX) Healthcare House Call Virtual Conference
Location: Virtual
Date: Thursday, May 28, 2026

A live webcast of the Sidoti fireside chat will be made available on Harvard Bioscience’s Investor Relations website. An archived replay of the webcast will be available following the event.

About Harvard Bioscience 

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

Company Contact:
Mark Frost
Chief Financial Officer
(508) 893-3120
[email protected]


Risks

  • Market reception to conference presentations and new information could remain unchanged, limiting stock movement.
  • Broader biotech and healthcare funding environment could affect investor interest and company valuation.
  • Competition and regulatory challenges inherent in biotech product development may limit growth potential.

More from Press Releases

Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference Oct 9, 2026 Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference Oct 9, 2026 Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia Oct 9, 2026 Aurora Mobile’s JPush Strengthens Shennong Group’s Messaging Infrastructure to Support Timely Delivery of Critical Business Information Oct 9, 2026 Wrap Appoints Veteran Law Enforcement Leader John “Chappy” Chapman as Vice President of Training and Missions Oct 9, 2026